WINDSOR, ON, Feb. 10, 2016 /PRNewswire/ - The President of New Venture Medical, Geoff Perry, has announced the release of an anti-radiation product from their Research and Development group. This is a revolutionary breakthrough in the treatment of cancer using radiation and the treating of environmental radiation exposure. It will assist in the healing of radiation burns, even when open sores are present. It will also protect only the healthy cells from radiation damage. It selectively helps and protects the healthy cells and not tumors.
The initial product is for radiation exposure and this will be available as an injectable liquid or as a sublingual pill or a topical cream. The product is designed to work at the subatomic level in the individual cell's mitochondria. It has significant impact not only in the treatment of cancer, but any exposure to radiation. It has the ability to penetrate through the brain/blood barrier enabling it to be effective against cell phone radiation emissions.
This is the first product released by NVMG. The company, over the next few months, will release a new product against even drug resistant malaria. It has shown to be effective at a 98% level in human tests, this includes drug resistant malaria. In as little as 15 days, even during the blood cycle of the disease, it has eliminated the parasite. There is currently no treatment effective during the blood cycle on the market.
There is a twin action HER/2 Breast cancer vaccine and a Lyme's disease vaccine under development. The HER/2 vaccine has a twin action. Current vaccines and others under development are useless if the cancer is present. NVMG's vaccine will work even if cancer is present. It initiates the standard vaccine response, but the vaccine also attacks that specific cancer cell as well.
Research data just reviewed indicate an ability to create a vaccine and treatment protocol for the Zika virus is viable and could be completed by the end of 2016.
SOURCE New Venture Medical Group